We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+23.4%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$145M
AUM Growth
+$10.7M
Cap. Flow
-$39.5M
Cap. Flow %
-27.17%
Top 10 Hldgs %
27.16%
Holding
316
New
137
Increased
28
Reduced
59
Closed
75

Top Buys

1
CNC icon
Centene
CNC
+$6.93M
2
IEF icon
iShares 7-10 Year Treasury Bond ETF
IEF
+$4.78M
3
UNH icon
UnitedHealth
UNH
+$3.65M
4
CVS icon
CVS Health
CVS
+$3.53M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.17M

Top Sells

1
HUM icon
Humana
HUM
+$4.91M
2
EHC icon
Encompass Health
EHC
+$3.58M
3
IBIT icon
iShares Bitcoin Trust
IBIT
+$3.43M
4
AMGN icon
Amgen
AMGN
+$3.35M
5
LLY icon
Eli Lilly
LLY
+$2.53M

Sector Composition

1 Healthcare 48.9%
2 Financials 13.82%
3 Technology 6.61%
4 Consumer Discretionary 5.8%
5 Materials 5.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
226
PMV Pharmaceuticals
PMVP
$71.5M
$3.63K ﹤0.01%
+2,589
New +$3.58K
CCCC icon
227
CALL
C4 Therapeutics
CCCC
$408M
$3.25K ﹤0.01%
+325
New +$780
JAZZ icon
228
PUT
Jazz Pharmaceuticals
JAZZ
$15.5B
$2.35K ﹤0.01%
+115
New +$13.8K
MRNA icon
229
CALL
Moderna
MRNA
$24.5B
$2.15K ﹤0.01%
249
– –
TLTW icon
230
PUT
iShares 20+ Year Treasury Bond BuyWrite Strategy ETF
TLTW
$1.87B
$1.86K ﹤0.01%
+621
New +$14.2K
LLY icon
231
PUT
Eli Lilly
LLY
$1.05T
$1.85K ﹤0.01%
23
-34,577
-100% -$25.7M
AEVA
232
CALL
Aeva Technologies
AEVA
$1.14B
$1.25K ﹤0.01%
+20
New +$379
APLT
233
CALL
DELISTED
Applied Therapeutics
APLT
$1.08K ﹤0.01%
+44
New +$21
FLNA
234
PUT
Filana Therapeutics
FLNA
$51.2M
$984 ﹤0.01%
24
-86,795
-100% -$200K
ATYR
235
CALL
aTyr Pharma
ATYR
$50M
$436 ﹤0.01%
297
– –
TVTX icon
236
PUT
Travere Therapeutics
TVTX
$5.27B
$390 ﹤0.01%
+1
New +$19
KOD icon
237
PUT
Kodiak Sciences
KOD
$2.67B
$145 ﹤0.01%
+3
New +$26
AUPH icon
238
PUT
Aurinia Pharmaceuticals
AUPH
$2.05B
$118 ﹤0.01%
+3
New +$33
MLTX icon
239
CALL
MoonLake Immunotherapeutics
MLTX
$1.64B
$36 ﹤0.01%
+61
New +$3.18K
HRMY icon
240
CALL
Harmony Biosciences
HRMY
$1.96B
$3 ﹤0.01%
+345
New +$11.9K
ACHC icon
241
Acadia Healthcare
ACHC
$3.17B
– –
-38,626
Closed -$876K
AFRM icon
242
Affirm
AFRM
$25.5B
– –
-10,989
Closed -$836K
ALT icon
243
PUT
Altimmune
ALT
$558M
– –
-19,081
Closed -$792K
AMGN icon
244
Amgen
AMGN
$198B
– –
-12,000
Closed -$3.35M
AMGN icon
245
PUT
Amgen
AMGN
$198B
– –
-659,413
Closed -$915K
ARGX icon
246
argenx
ARGX
$53.8B
– –
-1,377
Closed -$759K
ARVN icon
247
Arvinas
ARVN
$517M
– –
-22,233
Closed -$164K
BHVN icon
248
CALL
Biohaven
BHVN
$2.32B
– –
-230
Closed -$24.3K
BMEA icon
249
CALL
Biomea Fusion
BMEA
$92.5M
– –
-1,138
Closed -$2.34K
BPOP icon
250
Popular Inc
BPOP
$11.1B
– –
-6,566
Closed -$724K
8 9
10
11 12

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Persistent Asset Partners held 316 positions worth $145M, up 7.9% from $135M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Persistent Asset Partners withdrew a net $39.5M in Q3 2025, closing 75 positions and reducing 59 holdings. Its most notable exit was Humana, an estimated $4.91M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 52% a quarter earlier, followed by Financials and Technology.

Against the trend, Persistent Asset Partners opened a new position in Centene worth $8.19M.

  • Persistent Asset Partners's largest Q3 2025 buy was Centene: 229,544 shares worth $8.19M.
  • Persistent Asset Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $3.17M increase.
  • Persistent Asset Partners's biggest Q3 2025 reduction was iShares Bitcoin Trust, cutting an estimated $3.43M.
  • Persistent Asset Partners fully exited Humana in Q3 2025, selling an estimated $4.91M.
  • Persistent Asset Partners's ten largest holdings make up 27% of its $145M portfolio in Q3 2025.
  • Persistent Asset Partners opened 137 new positions and closed 75 in Q3 2025.
  • Persistent Asset Partners's portfolio value rose 7.9% quarter-over-quarter to $145M.

Based on Persistent Asset Partners's 13F filing for Q3 2025, filed 10 Nov 2025.